Pseudomonas aeruginosa exotoxin; IL-13 receptor α2 (IL-13RA2; IL-13R; CD213A2) BriefCommunication Pages: 1342 - 1342
Inhibitor of κ-light polypeptide gene enhancer in B cells kinase-ε (IKBKE; IKKε); Janus kinase (JAK) BriefCommunication Pages: 1343 - 1343
V-set domain containing T cell activation inhibitor 1 (B7-H4; VTCN1) BriefCommunication Pages: 1345 - 1345
Adenomatous polyposis coli (APC); BH3 interacting domain death agonist (BID) BriefCommunication Pages: 1347 - 1347
Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K) BriefCommunication Pages: 1348 - 1348
Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL); liver X receptor (LXR) BriefCommunication Pages: 1349 - 1349
SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 5 (SMARCA5; SNF2H); farnesyltransferase CAAX box-β (FNTB); microRNA-99 (miR-99); miR-100; microRNA let-7 (MIRLET7; LET-7) BriefCommunication Pages: 1350 - 1350
MicroRNA-188-3p (miR-188-3p); monoacylglycerol lipase (MAGL); β-site APP-cleaving enzyme 1 (BACE1) BriefCommunication Pages: 1354 - 1354
Transient receptor potential cation channel subfamily M member 2 (TRPM2); β-amyloid 40 (Aβ40); poly(ADP-ribose) polymerase (PARP) BriefCommunication Pages: 1355 - 1355
Ras/RAF/MEK/ERK pathway; Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) BriefCommunication Pages: 1356 - 1356
Ex vivo detection of indirect therapeutic protein–small molecule drug interactions on the liver BriefCommunication Pages: 1359 - 1359
Screening for diabetic cardiomyopathy (DCM) therapies in induced pluripotent stem (iPS) cell–derived cardiomyocytes BriefCommunication Pages: 1360 - 1360
Mice from the Collaborative Cross (CC) resource as models of Ebola viral infection BriefCommunication Pages: 1361 - 1361
Automated, in vitro generation of specific neuronal subtypes from human pluripotent stem cells BriefCommunication Pages: 1363 - 1363
Phage-assisted continuous evolution (PACE) to identify and predict drug-resistant protease mutations caused by protease inhibitors BriefCommunication Pages: 1364 - 1364